3862-85-9

Basic information

• Product Name: Hydrazinecarboxamide, 2-[(4-fluorophenyl)methylene]-
• CAS NO: 3862-85-9
• Molecular Formula: C8H8FN3O
• Molecular Weight: 181.169
• Mol File: 3862-85-9.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: Hydrazinecarboxamide, 2-[(4-fluorophenyl)methylene]-(CAS DataBase Reference)
• NIST Chemistry Reference: Hydrazinecarboxamide, 2-[(4-fluorophenyl)methylene]-(3862-85-9)
• EPA Substance Registry System: Hydrazinecarboxamide, 2-[(4-fluorophenyl)methylene]-(3862-85-9)

Safety Data

• Hazardous Substances Data: 3862-85-9(Hazardous Substances Data)

Upstream product

• 563-41-7 semicarbazide hydrochloride 
• 459-57-4 4-fluorobenzaldehyde 
• 4426-72-6 hydrazine carboxamide 

Downstream Products

• 7659-07-6 2-amino-5-(4-fluorophenyl)-1,3,4-oxadiazole 
• 1261138-34-4 3-(5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl)-2-phenylquinazolin-4(3H)-one 
• 1277127-61-3 C₁₅H₁₀FN₃O₂ 
• 1421633-72-8 C₉H₈FN₅O₂ 
• 1421633-61-5 C₉H₇FN₄O₂ 
• 1370641-56-7 2-[2-(4-fluorophenyl)-1,3,4-oxodiazol-5-yl]benzisoselenazol-3(2H)-one 
• 1338084-42-6 C₁₃H₈FN₅O₃ 
• 1338083-85-4 C₁₅H₁₂FN₅O₃ 
• 1338083-63-8 C₁₃H₉FN₆O₃ 
• 1338084-18-6 C₁₈H₁₇FN₆O₄ 

Relevant articles and documents

Ultrapotent Inhibitor of Clostridioides difficile Growth, Which Suppresses Recurrence in Vivo

Clostridioides difficile is the leading cause of healthcare-associated infection in the U.S. and considered an urgent threat by the Centers for Disease Control and Prevention (CDC). Only two antibiotics, vancomycin and fidaxomicin, are FDA-approved for the treatment of C. difficile infection (CDI), but these therapies still suffer from high treatment failure and recurrence. Therefore, new chemical entities to treat CDI are needed. Trifluoromethylthio-containing N-(1,3,4-oxadiazol-2-yl)benzamides displayed very potent activities [sub-μg/mL minimum inhibitory concentration (MIC) values] against Gram-positive bacteria. Here, we report remarkable antibacterial activity enhancement via halogen substitutions, which afforded new anti-C. difficile agents with ultrapotent activities [MICs as low as 0.003 μg/mL (0.007 μM)] that surpassed the activity of vancomycin against C. difficile clinical isolates. The most promising compound in the series, HSGN-218, is nontoxic to mammalian colon cells and is gut-restrictive. In addition, HSGN-218 protected mice from CDI recurrence. Not only does this work provide a potential clinical lead for the development of C. difficile therapeutics but also highlights dramatic drug potency enhancement via halogen substitution.

Ultrasound-assisted synthesis of 2-amino-1,3,4-oxadiazoles through NBS-mediated oxidative cyclization of semicarbazones

A ultrasound-assisted oxidative cyclization of semicarbazones using N-bromosuccinimide in the presence of sodium acetate was established providing efficient and rapid access to a variety of 2-amino-1,3,4-oxadiazoles. Moreover, the new synthetic protocol provides a simple procedure utilizing a safer oxidizing system that affords the target products in high regioselectivity, satisfactory yields, and elevated purities.

Synthesis and antitubercular activity of 2-(1H-pyrrol-1-Yl)-5- substituted-1,3,4-oxadiazoles

A series of 2-(1H-pyrrol-1-yl)-5-substituted-1,3,4-oxadiazole derivatives were prepared and evaluated for their antitubercular activity. These derivatives were synthesized by the reaction of 5-substituted-1,3,4-oxadiazol-2-amines (4a-j) with 2,5- dimethoxytetrahydrofuran in dried acetic acid. Structures of the newly synthesized compounds were confirmed on the basis of physico-chemical and spectral data. All the synthesized compounds were screened for their antitubercular activity using microplate almar blue assay (MABA) method. Compounds have shown moderate to good antitubercular activity against M. tuberculosis H37Rv microorganism.